Educated Patient® Breast Cancer Summit at MBCC Keynote Presentation: March 4, 2023

Video

Watch Dr. Anne O'Dea, from University of Kansas Medical Center, discuss targeting ESR1 mutations during the CURE Educated Patient® Breast Cancer Summit at MBCC.

At the CURE Educated Patient® Breast Cancer Summit, held live and virtually at the Miami Breast Cancer Conference, Dr. Anne O'Dea, medical director of breast cancer survivorship at the University of Kansas Medical Center, presented the keynote lecture, titled “A new era in the treatment of ER+, HER2- Advanced or Metastatic Breast Cancer: targeting ESR1 mutations.”

Educated Patient® Breast Cancer Summit at MBCC

Educated Patient® Breast Cancer Summit at the Miami Breast Cancer Conference, held March 4, 2023.

In particular, O’Dea discusses the need for new endocrine therapies to treat estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as well as results from the EMERAL trial, that led to the Food and Drug Administration approval of elacestrant (Orserdu) in this patient population.

Disclosure: O’Dea is a consultant and/or speaker for Gilead, DSI, Puma, Pfizer, Novartis and Stemline.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Image of a man with brown hair.
Image of a woman with short brown hair and glasses.
Image of a woman with short brown hair and glasses.
Image of a man with brown hair and a suit and tie.
Image of a woman with brown bobbed hair with glasses.
Image of Dr. Minesh Mehta at ASCO 2024.
Image of a woman with blond hai
Image of a man with rectangular glasses and short dark hair.
Image of a man with dark hair wearing a suit with a light blue tie.
Related Content
Image of a myeloma cell.

Multiple Myeloma Progression Still Slowed With Reduced Tecvayli Dosing

Alex Biese
June 17th 2024
Article

Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli.

Read More

cancer horizons image for podcast

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon;Alex Biese
December 14th 2023
Podcast

CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.

Listen

Illustration of a man holding a magnifying glass over paperwork.

Determining Stem Cell Transplant Eligibility, Quality of Life in Myeloma

Ashley Chan
June 13th 2024
Article

Quality of life may temporarily worsen after patients with myeloma receive stem cell transplants, said an expert at the Educated Patient® Multiple Myeloma Summit.

Read More

Cancer Horizons podcast logo

Conference Highlights from SABCS

Alex Biese;Brielle Benyon
December 12th 2023
Podcast

CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.

Listen

multiple myeloma cells

Tecvayli Responses Continue for Two Years in R/R Multiple Myeloma

Alex Biese
June 10th 2024
Article

Data from the MajesTEC-1 trial shows that patients with relapsed/refractory multiple myeloma responded to Tecvalyi for a median of two years and lived without disease progression for nearly a year.

Read More

image of a paper that says multiple myeloma with pills.

4-Drug Regimen Boosts Time to Progression in Newly Diagnosed Myeloma

Ryan Scott
June 8th 2024
Article

Sarclisa, Velcade, Revlimid and dexamethasone improved progression-free survival in patients with multiple myeloma who were not eligible for transplant.

Read More